Top

Published in:

01-04-2022 | Respiratory Microbiota | Original Article

Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis

Authors: Zhiyuan Hao, Kegong Tao, Kaiming Wu, Yuanyuan Luo, Yiting Lu, Binbin Li, Peimei Shi, Peiqin Wang, Xin Zeng, Yong Lin

Published in: Hepatology International | Issue 2/2022

Abstract

Background and aims

Gut microbiota and their metabolic products might play important roles in regulating the pathogenesis of choledocholithiasis concurrent with cholangitis (CC). The aim of this study was to explore the characteristic gut dysbiosis, metabolite profiles and the possible roles in patients with CC.

Methods

A case–control study was carried out to analyze the alterations in the intestinal microbiota and their metabolites in patients with CC (n = 25) compared with healthy controls (HCs) (n = 25) by metagenomic sequencing to define the gut microbiota community and liquid chromatography/mass spectrometry (LC/MS) analysis to characterize the metabolite profiles.

Results

Significantly reduced Shannon diversity index (p = 0.043) and differential overall fecal microbiota community in CCs were observed. Twelve dominant altered species were identified and analyzed (LDA score > 3.0, p < 0.05) (Q value < 0.05), including unclassified_f_Enterobacteriaceae, Escherichia_coli, Roseburia_faecis and Eubacterium rectale. Moreover, the levels of KEGG pathways related to biofilm formation of Escherichia coli, lipopolysaccharide (LPS) biosynthesis, and the metabolism of propanoate and glutathione in CCs were significantly altered. Finally, 47 markedly changed metabolites (VIP > 1.0 and p < 0.05), including low level of kynurenic acid (KYNA) and high concentration of N-palmitoylsphingosine involving tryptophan metabolism and sphingolipid signaling pathways, were identified to validate aberrant metabolic patterns in CCs, and multiple correlated metabolic modules involving bile inflammation were altered in CCs.

Conclusion

Our study provides novel insights into compositional and functional alterations in the gut microbiome and metabolite profiles in CC and the underlying mechanisms between gut microbiota and bile inflammation.

Available only for authorised users

Frossard JL, Morel PM. Detection and management of bile duct stones. Gastrointest Endosc. 2010;72(4):808–16. https://doi.org/10.1016/j.gie.2010.06.033.CrossRefPubMed

Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149(7):1731-1741.e3. https://doi.org/10.1053/j.gastro.2015.08.045.CrossRefPubMed

ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019;89(6):1075–105. https://doi.org/10.1016/j.gie.2018.10.001.CrossRef

Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med. 1992;326(24):1582–6. https://doi.org/10.1056/NEJM199206113262401.CrossRefPubMed

Negm AA, Schott A, Vonberg RP, et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc. 2010;72(2):284–91. https://doi.org/10.1016/j.gie.2010.02.043.CrossRefPubMed

Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024. https://doi.org/10.1038/nrdp.2016.24.CrossRefPubMed

Van Erpecum KJ, Van Berge-Henegouwen GP. Gallstones: an intestinal disease? Gut. 1999;44(3):435–8. https://doi.org/10.1136/gut.44.3.435.CrossRefPubMed

Wang HH, Portincasa P, Mendez-Sanchez N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology. 2008;134(7):2101–10. https://doi.org/10.1053/j.gastro.2008.03.011.CrossRefPubMed

Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol. 2012;36(2):122–9. https://doi.org/10.1016/j.clinre.2011.08.010.CrossRefPubMed

10.

Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411. https://doi.org/10.1038/s41575-018-0011-z.CrossRefPubMedPubMedCentral

11.

Sun J, Chang EB. Exploring gut microbes in human health and disease: pushing the envelope. Genes Dis. 2014;1(2):132–9. https://doi.org/10.1016/j.gendis.2014.08.001.CrossRefPubMedPubMedCentral

12.

Wang Q, Jiao L, He C, et al. Alteration of gut microbiota in association with cholesterol gallstone formation in mice. BMC Gastroenterol. 2017;17(1):74. https://doi.org/10.1186/s12876-017-0629-2.CrossRefPubMedPubMedCentral

13.

Verdier J, Luedde T, Sellge G. Biliary mucosal barrier and microbiome. Viszeralmedizin. 2015;31(3):156–61. https://doi.org/10.1159/000431071.CrossRefPubMedPubMedCentral

14.

Sayin SI, Wahlström A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225–35. https://doi.org/10.1016/j.cmet.2013.01.003.CrossRefPubMed

15.

Wu T, Zhang Z, Liu B, et al. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics. 2013;14:669. https://doi.org/10.1186/1471-2164-14-669.CrossRefPubMedPubMedCentral

16.

Liu J, Yan Q, Luo F, et al. Acute cholecystitis associated with infection of Enterobacteriaceae from gut microbiota. Clin Microbiol Infect. 2015;21(9):851.e1-9. https://doi.org/10.1016/j.cmi.2015.05.017.CrossRef

17.

Capoor MR, Nair D, Rajni, et al. Microflora of bile aspirates in patients with acute cholecystitis with or without cholelithiasis: a tropical experience. Braz J Infect Dis. 2008;12(3):222–5. https://doi.org/10.1590/s1413-86702008000300012.CrossRefPubMed

18.

Chen B, Fu SW, Lu L, et al. A preliminary study of biliary microbiota in patients with bile duct stones or distal cholangiocarcinoma. Biomed Res Int. 2019;2019:1092563. https://doi.org/10.1155/2019/1092563.CrossRefPubMedPubMedCentral

19.

Feng J, Zhao F, Sun J, et al. Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients. Int J Cancer. 2019;144(11):2728–45. https://doi.org/10.1002/ijc.32007.CrossRefPubMed

20.

Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77. https://doi.org/10.1016/j.jhep.2019.10.003.CrossRefPubMed

21.

Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020;69(3):569–77. https://doi.org/10.1136/gutjnl-2018-317836.CrossRefPubMed

22.

Xue F, Nan X, Sun F, et al. Metagenome sequencing to analyze the impacts of thiamine supplementation on ruminal fungi in dairy cows fed high-concentrate diets. AMB Express. 2018;8(1):159. https://doi.org/10.1186/s13568-018-0680-6.CrossRefPubMedPubMedCentral

23.

Li R, Li Y, Kristiansen K, et al. SOAP: short oligonucleotide alignment program. Bioinformatics. 2008;24(5):713–4. https://doi.org/10.1093/bioinformatics/btn025.CrossRefPubMed

24.

Peng W, Yi P, Yang J, et al. Association of gut microbiota composition and function with a senescence-accelerated mouse model of Alzheimer’s Disease using 16S rRNA gene and metagenomic sequencing analysis. Aging (Albany NY). 2018;10(12):4054–65. https://doi.org/10.18632/aging.101693.CrossRef

25.

Quinn RA, Melnik AV, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579(7797):123–9. https://doi.org/10.1038/s41586-020-2047-9.CrossRefPubMedPubMedCentral

26.

Adams LA, Wang Z, Liddle C, et al. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2020;40(6):1356–65. https://doi.org/10.1111/liv.14453.CrossRefPubMed

27.

Cresci GAM. Is it time to consider gut microbiome readouts for precision diagnosis and treatment of alcoholic liver disease? Hepatology. 2020;72(1):4–6. https://doi.org/10.1002/hep.31245.CrossRefPubMed

28.

Schwabe RF, Greten TF. Gut microbiome in HCC—mechanisms, diagnosis and therapy. J Hepatol. 2020;72(2):230–8. https://doi.org/10.1016/j.jhep.2019.08.016.CrossRefPubMed

29.

Friedfeld MR, Zhong H, Ruck RT, et al. Cobalt-catalyzed asymmetric hydrogenation of enamides enabled by single-electron reduction. Science. 2018;360(6391):888–93. https://doi.org/10.1126/science.aar6117.CrossRefPubMed

30.

Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68(6):1014–23. https://doi.org/10.1136/gutjnl-2017-315084.CrossRefPubMed

31.

Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34(2):71–80. https://doi.org/10.1097/MOG.0000000000000423.CrossRefPubMedPubMedCentral

32.

Levy M, Kolodziejczyk AA, Thaiss CA, et al. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219–32. https://doi.org/10.1038/nri.2017.7.CrossRefPubMed

33.

Razaghi M, Tajeddin E, Ganji L, et al. Colonization, resistance to bile, and virulence properties of Escherichia coli strains: unusual characteristics associated with biliary tract diseases. Microb Pathog. 2017;111:262–8. https://doi.org/10.1016/j.micpath.2017.08.043.CrossRefPubMed

34.

Zhao J, Wang Q, Zhang J. Changes in microbial profiles and antibiotic resistance patterns in patients with biliary tract infection over a six-year period. Surg Infect (Larchmt). 2019;20(6):480–5. https://doi.org/10.1089/sur.2019.041.CrossRef

35.

Mizutani T, Mitsuoka T. Inhibitory effect of some intestinal bacteria on liver tumorigenesis in gnotobiotic C3H/He male mice. Cancer Lett. 1980;11(2):89–95. https://doi.org/10.1016/0304-3835(80)90098-1.CrossRefPubMed

36.

Pittayanon R, Lau JT, Leontiadis GI, et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology. 2020;158(4):930-946.e1. https://doi.org/10.1053/j.gastro.2019.11.294.CrossRefPubMed

37.

Li KY, Wang JL, Wei JP, et al. Fecal microbiota in pouchitis and ulcerative colitis. World J Gastroenterol. 2016;22(40):8929–39. https://doi.org/10.3748/wjg.v22.i40.8929.CrossRefPubMedPubMedCentral

38.

David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63. https://doi.org/10.1038/nature12820.CrossRefPubMed

39.

Chia JH, Feng Y, Su LH, et al. Clostridium innocuum is a significant vancomycin-resistant pathogen for extraintestinal clostridial infection. Clin Microbiol Infect. 2017;23(8):560–6. https://doi.org/10.1016/j.cmi.2017.02.025.CrossRefPubMed

40.

Feng Q, Liu Z, Zhong S, et al. Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease. Sci Rep. 2016;6:22525. https://doi.org/10.1038/srep22525.CrossRefPubMedPubMedCentral

41.

Ferrero MA, Martínez-Blanco H, Lopez-Velasco FF, et al. Purification and characterization of GlcNAc-6-P 2-epimerase from Escherichia coli K92. Acta Biochim Pol. 2007;54(2):387–99.CrossRefPubMed

42.

Martin G, Kolida S, Marchesi JR, et al. In vitro modeling of bile acid processing by the human fecal microbiota. Front Microbiol. 2018;9:1153. https://doi.org/10.3389/fmicb.2018.01153.CrossRefPubMedPubMedCentral

43.

Lee JH, Regmi SC, Kim JA, et al. Apple flavonoid phloretin inhibits Escherichia coli O157:H7 biofilm formation and ameliorates colon inflammation in rats. Infect Immun. 2011;79(12):4819–4127. https://doi.org/10.1128/IAI.05580-11.CrossRefPubMedPubMedCentral

44.

Niu GC, Liu L, Zheng L, et al. Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice. BMC Gastroenterol. 2018;18(1):127. https://doi.org/10.1186/s12876-018-0850-7.CrossRefPubMedPubMedCentral

45.

Yokoyama T, Komori A, Nakamura M, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int. 2006;26(4):467–76. https://doi.org/10.1111/j.1478-3231.2006.01254.x.CrossRefPubMed

46.

Zhang Y, Yu W, Han D, et al. L-lysine ameliorates sepsis-induced acute lung injury in a lipopolysaccharide-induced mouse model. Biomed Pharmacother. 2019;118: 109307. https://doi.org/10.1016/j.biopha.2019.109307.CrossRefPubMed

47.

Jiao N, Baker SS, Nugent CA, et al. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: a meta-analysis. Physiol Genomics. 2018;50(4):244–54. https://doi.org/10.1152/physiolgenomics.00114.2017.CrossRefPubMed

48.

Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–5. https://doi.org/10.1038/nature12726.CrossRefPubMedPubMedCentral

49.

Cani PD. Is colonic propionate delivery a novel solution to improve metabolism and inflammation in overweight or obese subjects? Gut. 2019;68(8):1352–3. https://doi.org/10.1136/gutjnl-2019-318776.CrossRefPubMed

50.

Ciocan D, Voican CS, Wrzosek L, et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis. Aliment Pharmacol Ther. 2018;48(9):961–74. https://doi.org/10.1111/apt.14949.CrossRefPubMed

51.

Wirthgen E, Hoeflich A, Rebl A, et al. Kynurenic Acid: the Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front Immunol. 2018;8:1957. https://doi.org/10.3389/fimmu.2017.01957.CrossRefPubMedPubMedCentral

52.

Marciniak S, Wnorowski A, Smolińska K, et al. Kynurenic Acid protects against thioacetamide-induced liver injury in rats. Anal Cell Pathol (Amst). 2018;2018:1270483. https://doi.org/10.1155/2018/1270483.CrossRef

53.

Moroni F, Cozzi A, Sili M, et al. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm (Vienna). 2012;119(2):133–9. https://doi.org/10.1007/s00702-011-0763-x.CrossRef

54.

Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600. https://doi.org/10.1038/nri3707.CrossRefPubMedPubMedCentral

55.

Raichur S, Brunner B, Bielohuby M, et al. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach. Mol Metab. 2019;21:36–50. https://doi.org/10.1016/j.molmet.2018.12.008.CrossRefPubMedPubMedCentral

56.

Albeituni S, Stiban J. Roles of ceramides and other sphingolipids in immune cell function and inflammation. Adv Exp Med Biol. 2019;1161:169–91. https://doi.org/10.1007/978-3-030-21735-8_15.CrossRefPubMed

57.

Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–95. https://doi.org/10.1016/j.jhep.2017.11.014.CrossRefPubMed

58.

Chaurasia B, Tippetts TS, Mayoral Monibas R, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science. 2019;365(6451):386–92. https://doi.org/10.1126/science.aav3722.CrossRefPubMedPubMedCentral

Title: Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis
Authors: Zhiyuan Hao
Kegong Tao
Kaiming Wu
Yuanyuan Luo
Yiting Lu
Binbin Li
Peimei Shi
Peiqin Wang
Xin Zeng
Yong Lin
Publication date: 01-04-2022
Publisher: Springer India
Keywords: Respiratory Microbiota
Cholangitis
Choledocholithiasis
Published in: Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-021-10231-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2022

Is lean non-alcoholic fatty liver disease a distinct entity?

Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial

Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study

A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients

Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?

MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage